JMJeffrey N. Motter

Jeffrey N. Motter

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jeffrey N. Motter has a total of 52 co-authors. Here are the top co-authors by number of shared publications:

  • Davangere P. Devanand

    From the Department of Psychiatry (J.N.M., S.L., T.E.G., D.P.D.), Columbia University, New York; Division of Geriatric Psychiatry (J.N.M., T.E.G., D.P.D.), and Division of Mental Health Data Science (J.C., S.L.), New York State Psychiatric Institute, New York; Department of Biostatistics (S.L.), Columbia University, New York, NY; and Department of Behavioral and Community Health Sciences (S.A.), Graduate School of Public Health, University of Pittsburgh, PA

    6 shared publications
  • P. Murali Doraiswamy

    Department of Psychiatry and Behavioral Sciences, Duke University Health System

    5 shared publications
  • Joel R. Sneed

    Queens College The Graduate Center Clinical Neuropsychologist City University of New York New York NY USA

    4 shared publications
  • Joel R. Sneed

    Columbia University and the New York State Psychiatric Institute

    3 shared publications
  • Seonjoo Lee

    New York State Psychiatric Institute, New York, NY USA

    3 shared publications
  • D.P. Devanand

    Columbia University and the New York State Psychiatric Institute

    2 shared publications

Latest Publications

  • Open Access

    Depression, Anxiety, and Neuropsychiatric Symptom Burden in a Longitudinal Cohort with Persistent Psychophysical Post-COVID Olfactory Dysfunction

    by Tiana M. Saak, Jeremy P. Tervo, Brandon J. Vilarello, Patricia T. Jacobson, Francesco F. Caruana, Matthew D. A. Spence, Liam W. Gallagher, David A. Gudis, Jeffrey N. Motter, Davangere P. Devanand, et al.

    Background/Objectives: Olfactory dysfunction (OD) is associated with a variety of neurologic deficits and impacts socialization decisions, mood, and overall quality of life. As a common symptom comprising the long COVID condition, persistent COVID-19-associated olfactory dysfunction (C19OD) may further impact the presentations of neuropsychiatric sequelae. Our study aims to characterize the longitudinal burden of depression, anxiety, and neuropsychiatric symptoms in a population with C19OD. Methods: Individuals with perceived C19OD completed a psychophysical screening evaluation of their sense of smell using the comprehensive Sniffin’ Sticks olfactory assessment. Only those with validated psychophysical OD were included in this prospective longitudinal study for baseline and one-year follow-up. Participants also completed PHQ-9, Beck Anxiety Inventory (BAI), and neuropsychiatric symptom questionnaires at each time point. Anxiety, depression, and neuropsychiatric symptom prevalence was calculated and compared between time points with Pearson’s chi-squared, Fisher’s exact, and Wilcoxon rank sum tests. Results: Each neuropsychiatric symptom evaluated in this study was reported by 13–49% of longitudinal cohort participants at both baseline and follow-up, except for seizure (0% at baseline and follow-up) and word-finding difficulty (61–68% at baseline and follow-up). Word-finding and focus difficulties were the most commonly reported symptoms. In total, 41% of participants reported some level of depression at baseline and 38% of participants reported depression at one-year follow-up, while 29% and 27% of participants reported some level of anxiety at respective time points. Conclusions: Individuals with C19OD are at risk for developing persistent neuropsychiatric conditions. These neurologic and psychiatric sequelae are persistent with repeated longitudinal assessment, even at nearly 2.5 years following initial COVID-19 diagnosis.


  • Open Access

    Accuracy of intact performance on measures of odor identification, global cognition, and amyloid imaging for identifying lack of cognitive decline and dementia in the Mayo Clinic Study of Aging cohort

    by Jeffrey N Motter, Seonjoo Lee, David S. Knopman, Maria Vassilaki, Davangere Devanand

    Background: Previous studies have linked impaired odor identification and global cognition with increased risk of cognitive decline and transition to dementia. However, the reverse question remains: if individuals have intact performance on these measures, are they at reduced risk for transition? We aimed to examine the accuracy of intact odor identification and global cognition for identifying lack of transition to dementia/cognitive decline using the population‐based Mayo Clinic Study of Aging and compare their accuracy against and in combination with amyloid PET (Positron Emission Tomography).Method: n = 647 participants age≥55 without dementia completed at baseline the Brief Smell Identification Test (BSIT; ‘Intact’ = 9‐12), Blessed Information‐Memory‐Concentration Test (BIMCT; ‘Intact’ = 18‐20,), and amyloid PET (‘Normal/Intact’ SUVR<1.48). We calculated sensitivity, specificity, positive predictive value, and negative predictive value for these measures, with “lack of transition to dementia” as the gold standard/target. “Lack of cognitive decline” (cognitively unimpaired to mild cognitive impairment [MCI]; cognitively unimpaired to dementia; or MCI to dementia) was a secondary target.Result: 94.7% of participants (613/647) did not transition to dementia and 84.2% (545/647) did not cognitively decline over 11.25‐year‐follow‐up. The combination of intact BSIT+BIMCT had high rates of lack of transition to dementia (98.3%, 355/361) and lack of cognitive decline (93.1%, 336/361). This combination yielded mixed sensitivity (0.579) and specificity (0.824) though had high positive predictive value (0.983) for identifying lack of transition to dementia. Intact amyloid PET alone exhibited comparable rates of lack of transition to dementia (99.0%, 418/423) and lack of cognitive decline (92.4%, 391/423). When evaluated conjointly, the combination of all three intact measures also had mixed sensitivity (0.421) and specificity (0.962) though higher positive predictive value (PPV = 0.996) for lack of transition to dementia. 99.6% (258/259) of participants with intact/normal status on all three did not transition to dementia and 96.5% (250/259) did not cognitively decline.Conclusion: This replicates prior reports that intact olfaction/global cognition have strong utility for identifying individuals unlikely to develop MCI/dementia. Intact/normal amyloid PET further enhances the positive predictive value. Clinically, identifying individuals at low risk of transition can shorten diagnostic workups, reduce need for early follow‐up visits, and screen patients in‐or‐out of clinical trials.

  • Association of Performance on Olfactory and Cognitive Screening Tests With Conversion to Dementia in a Biracial Cohort of Older Adults

    by Jeffrey N. Motter, Jongwoo Choi, Seonjoo Lee, Terry E. Goldberg, Steven Albert, Davangere P. Devanand

    Background and Objectives: Odor identification deficits are associated with transition to dementia, whereas intact odor identification and global cognition test performance may identify lack of transition. The purpose of this study is to examine intact odor identification and global cognition as prognostic indicators of lack of transition to dementia in a biracial (Black and White) cohort. Methods: In a community-dwelling sample of older adults from the Health, Aging, and Body Composition (Health ABC) study, odor identification was measured using the Brief Smell Identification Test (BSIT) and global cognition was measured using the Teng Modified Mini-Mental Status Examination (3MS). Survival analyses for dementia transition over 4 and 8 years of follow-up utilized Cox proportional-hazards models. Results: The n=2240 participants had an average age of 75.5 years (SD 2.8). 52.7% were female. 36.7% were Black and 63.3% were White. Impaired odor identification (HR=2.29, 95% CI=1.79-2.94, p<0.001) and global cognition (HR=3.31, 95% CI=2.26-4.84, p<0.001) were each independently associated with transition to dementia (n=281). Odor identification remained robustly associated with transition to dementia for Black (HR=2.02, 95% CI=1.36-3.00, p<0.001, n=821) and White participants (HR=2.45, 95% CI=1.77-3.38, p<0.001, n=1419), whereas global cognition was associated with transition among Black participants only (HR=5.06, 95% CI=3.18-8.07, p<0.001). ApoE genotype was consistently associated with transition among White participants only (HR=1.75, 95% CI=1.20-2.54, p<0.01). Among participants with intact performance on both odor identification (BSIT ≥9/12 correct) and global cognition (3MS ≥78/100 correct), 8.8% transitioned to dementia over 8 years. Intact performance on both measures had high positive predictive value for identifying individuals who did not transition to dementia over 4 years (0.98 for ages 70-75 with only 2.3% transitioning, 0.94 for ages 76-82 with only 5.8% transitioning). Discussion: Odor identification testing paired with a global cognitive screening test identified individuals at low risk for transition to dementia in a biracial community cohort with a pronounced effect in the eighth decade of life. Identification of such individuals can reduce the need for extensive investigation to establish a diagnosis. Odor identification deficits showed utility in both Black and White participants, unlike the race-dependent utility of a global cognitive test and ApoE genotype.


  • Open Access

    Expectancy Does Not Predict 18-month Treatment Outcomes with Cognitive Training in Mild Cognitive Impairment

    by Jeffrey N. Motter, S. N. Rushia, M. Qian, C. Ndouli, A. Nwosu, J. R. Petrella, P. M. Doraiswamy, T. E. Goldberg, D. P. Devanand

    Computerized cognitive training (CCT) has emerged as a potential treatment option for mild cognitive impairment (MCI). It remains unclear whether CCT’


  • Cortical thickness predicts remission of depression with antidepressants in patients with late-life depression and cognitive impairment

    by Jeffrey N. Motter, Seonjoo Lee, Joel R. Sneed, P. Murali Doraiswamy, Gregory H. Pelton, Jeffrey R. Petrella, D.P. Devanand


  • Open Access

    Odor identification impairment and cholinesterase inhibitor treatment in Alzheimer's disease

    by Jeffrey N. Motter, Xinhua Liu, Min Qian, Hannah R. Cohen, Davangere P. Devanand

    Introduction: This study evaluated acute change in odor identification following atropine nasal spray challenge, and 8‐week change in odor identification ability, as a predictor of long‐term improvement in patients with mild to moderate Alzheimer's disease (AD) who received open‐label cholinesterase inhibitor treatment. Methods: In patients with clinical AD, the University of Pennsylvania Smell identification Test (UPSIT) was administered before and after an anticholinergic atropine nasal spray challenge. Patients were then treated with donepezil for 52 weeks. Results: In 21 study participants, acute atropine‐induced decrease in UPSIT was not associated with change in the Alzheimer's Disease Assessment Scale ‐ Cognitive Subscale (ADAS‐Cog) or Selective Reminding Test (SRT). Decline in odor identification performance from baseline to week 8 was indicative of a future decline in cognitive performance over 52 weeks. Discussion: Change in odor identification with atropine challenge is not a useful predictor of treatment response to cholinesterase inhibitors. Short‐term change in odor identification performance needs further investigation as a potential predictor of cognitive improvement with cholinesterase inhibitor treatment.


  • Odorant‐induced brain activation as a function of normal aging and Alzheimer’s disease

    by Jeffrey N. Motter, Jason Steffener, Matthias H. Tabert, Davangere P. Devanand

    Background: Olfactory dysfunction consistently occurs in patients with Alzheimer’s disease (AD), beyond the mild and gradual decline in olfactory ability found in normal aging. This dysfunction begins early in the disease course, typically before clinical diagnosis, and progresses with disease severity. While odor identification and detection deficits clearly differentiate AD from controls, there remains uncertainty as to whether these are determined by olfactory threshold. The primary purpose of the current fMRI study was to examine the neural correlates of olfactory processing in healthy young and old adults and compare them with AD patients.Method: Health young adults (n=10), healthy old adults (n=10), and AD patients (n=12) participated in psychophysical olfactory testing and an fMRI odorant detection paradigm. We analyzed the interplay between age and disease‐related psychophysical olfactory declines and odorant‐induced brain activation. This tested whether odor threshold deficits reflect disease progression and explain group differences in detection, identification and brain activity.Result: AD patients had decreased odor detection task‐related signal in all regions of the primary olfactory cortex, with activity in the entorhinal cortex best differentiating the groups. Within the secondary olfactory regions, AD patients showed decreased activity in orbitofrontal cortex compared to healthy age matched individuals. Moderated‐mediation analyses on neuro‐psychophysical relationships found that increased brain activation in the entorhinal cortex moderated the negative effect of disease‐related threshold decline on olfactory detection.Conclusion: Even in the face of declining olfactory thresholds, older adults compensated for this effect with increased brain activation in a primary olfactory brain region. This was the case for odor detection but not odor identification. fMRI activation induced by an olfactory identification task may eventually be useful in improving early detection of AD and may, eventually, facilitate early treatment interventions in subjects at risk for AD.